These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26358287)

  • 1. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
    Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
    Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
    Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of Jusline following subcutaneous administration in healthy subjects.
    Al-Rubeaan KA; Al-Daghri NM; Alkharfy KM; Al-Attas OS; Hanif FS; Metias NS; Sabico SL
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):382-8. PubMed ID: 18793592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes.
    Lucidi P; Porcellati F; Marinelli Andreoli A; Candeloro P; Cioli P; Bolli GB; Fanelli CG
    Diabetes Metab; 2018 Sep; 44(4):368-372. PubMed ID: 28599764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
    Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
    Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
    Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
    Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
    Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
    Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
    Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
    Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
    Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
    Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.